Gynaecological Cancer Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Report
170 Pages
November 2023
Region: Global
Fairfield Market Research
ID: 5910759

Gynaecological cancers are on the rise and have become a leading cause of death in various regions, prompting a surge in research and innovation within the pharmaceutical industry. A new report reveals key insights into the global gynaecological cancer drugs market, highlighting trends, projections, and key players in the field.

Antitumor Antibiotic Class Takes Center Stage Among the various drug classes, antitumor antibiotics are poised to gain the most traction in the global gynaecological cancer drugs market, with a projected revenue of over US$ 13,700 million by 2026. These antibiotics play a crucial role in halting or slowing the multiplication of cancer cells, demonstrating their effectiveness in treating gynaecological cancers.

Hospitals Lead as Major End-Users Hospitals are expected to emerge as the largest end-users of gynaecological cancer drugs between 2017 and 2026. The availability of advanced cancer diagnosis and treatment facilities in hospitals has led to an increasing number of patients seeking care. Government and private sector investments in hospitals, along with the presence of specialist surgeons, have further fueled the demand for gynaecological cancer drugs.

Uterine Cancer Dominates the Market Uterine cancer is projected to account for the largest share of revenue in the global gynaecological cancer drugs market during the forecast period of 2017-2026. This type of cancer is the most commonly diagnosed among women, driving the discovery of new therapies and drugs for its treatment. Endometrial cancer, affecting the inner lining of the uterus, ranks as the second most common type of cancer among women, particularly in developed countries.

Hospital Pharmacies as Key Distribution Channels Among various distribution channels, hospital pharmacies are anticipated to be the largest, creating significant opportunities between 2017 and 2026. Government hospitals often exclusively sell many gynaecological cancer drugs through hospital pharmacies. The increasing availability of generic drugs for cancer treatment is also contributing to the growth of sales through hospital pharmacies.

North America Leads in Revenue Generation North America is poised to emerge as the major revenue-generating market for gynaecological cancer drugs, primarily due to the high prevalence of these cancers in the region. Europe and Asia Pacific Excluding Japan (APEJ) are also expected to witness substantial growth in the coming years. Ongoing research, development, and clinical trials of drugs in the United States are driving market growth in North America.

Key Players in the Competitive Landscape Key companies in the global gynaecological cancer drugs market include GlaxoSmithKline (GSK), Johnson & Johnson (Alza Corporation), Dr. Reddy’s Laboratories, Merck & Co., Bristol-Myers Squibb, Takeda Pharmaceuticals Co. Ltd, Pfizer Inc, Eli Lilly & Co., Sanofi, AstraZeneca, and Roche Holdings AG.

Global Gynaecological Cancer Drugs Market- Segmentation

Drug Class

Alkylating Agent
Plant Alkaloid
Anthracyclines
Antitumor Antibiotic
Other Drug Class

End Users

Hospitals
Clinics
Specialized Cancer Treatment Centers
Other End Users

Indication

Cervical Cancer
Uterine Cancer
Ovarian & Fallopian Tube Cancer
Vulvar Cancer
Vaginal Cancer

Distribution Channel

Hospital Pharmacies
Retail Pharmacies
E-commerce

Region

North America
Latin America
Europe
Japan
APEJ
MEA

This product will be delivered within 1-3 business days.

1. Executive Summary

1.1. Global Gynaecological Cancer Drugs Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value and Volume, 2022
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter’s Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

3.1. Global Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
3.1.1. Key Highlights
3.1.1.1. Alkylating Agent
3.1.1.2. Plant Alkaloid
3.1.1.3. Anthracyclines
3.1.1.4. Antitumor Antibiotic
3.1.1.5. Other Drug Class
3.2. Global Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
3.2.1. Key Highlights
3.2.1.1. Cervical Cancer
3.2.1.2. Uterine Cancer
3.2.1.3. Ovarian & Fallopian Tube Cancer
3.2.1.4. Vulvar Cancer
3.2.1.5. Vaginal Cancer
3.3. Global Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
3.3.1. Key Highlights
3.3.1.1. Hospital Pharmacies
3.3.1.2. Retail Pharmacies
3.3.1.3. E-commerce
3.4. Global Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
3.4.1. Key Highlights
3.4.1.1. Hospitals
3.4.1.2. Clinics
3.4.1.3. Specialized Cancer Treatment Centers
3.4.1.4. Other End Users
3.5. Global Gynaecological Cancer Drugs Market Outlook, by Region, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
3.5.1. Key Highlights
3.5.1.1. North America
3.5.1.2. Europe
3.5.1.3. Asia Pacific
3.5.1.4. Latin America
3.5.1.5. Middle East & Africa

4. North America Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

4.1. North America Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.1.1. Key Highlights
4.1.1.1. Alkylating Agent
4.1.1.2. Plant Alkaloid
4.1.1.3. Anthracyclines
4.1.1.4. Antitumor Antibiotic
4.1.1.5. Other Drug Class
4.2. North America Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.2.1. Key Highlights
4.2.1.1. Cervical Cancer
4.2.1.2. Uterine Cancer
4.2.1.3. Ovarian & Fallopian Tube Cancer
4.2.1.4. Vulvar Cancer
4.2.1.5. Vaginal Cancer
4.3. North America Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.3.1. Key Highlights
4.3.1.1. Hospital Pharmacies
4.3.1.2. Retail Pharmacies
4.3.1.3. E-commerce
4.4. North America Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.4.1. Key Highlights
4.4.1.1. Hospitals
4.4.1.2. Clinics
4.4.1.3. Specialized Cancer Treatment Centers
4.4.1.4. Other End Users
4.5. North America Gynaecological Cancer Drugs Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1. Key Highlights
4.5.1.1. U.S. Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.2. U.S. Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.3. U.S. Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.4. U.S. Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.5. Canada Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.6. Canada Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.7. Canada Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.1.8. Canada Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
4.5.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

5.1. Europe Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.1.1. Key Highlights
5.1.1.1. Alkylating Agent
5.1.1.2. Plant Alkaloid
5.1.1.3. Anthracyclines
5.1.1.4. Antitumor Antibiotic
5.1.1.5. Other Drug Class
5.2. Europe Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.2.1. Key Highlights
5.2.1.1. Cervical Cancer
5.2.1.2. Uterine Cancer
5.2.1.3. Ovarian & Fallopian Tube Cancer
5.2.1.4. Vulvar Cancer
5.2.1.5. Vaginal Cancer
5.3. Europe Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.3.1. Key Highlights
5.3.1.1. Hospital Pharmacies
5.3.1.2. Retail Pharmacies
5.3.1.3. E-commerce
5.4. Europe Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.4.1. Key Highlights
5.4.1.1. Hospitals
5.4.1.2. Clinics
5.4.1.3. Specialized Cancer Treatment Centers
5.4.1.4. Other End Users
5.5. Europe Gynaecological Cancer Drugs Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1. Key Highlights
5.5.1.1. Germany Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.2. Germany Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.3. Germany Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.4. Germany Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.5. U.K. Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.6. U.K. Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.7. U.K. Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.8. U.K. Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.9. France Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.10. France Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.11. France Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.12. France Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.13. Italy Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.14. Italy Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.15. Italy Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.16. Italy Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.17. Turkey Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.18. Turkey Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.19. Turkey Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.20. Turkey Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.21. Russia Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.22. Russia Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.23. Russia Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.24. Russia Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.25. Rest of Europe Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.26. Rest of Europe Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.27. Rest of Europe Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.1.28. Rest of Europe Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
5.5.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

6.1. Asia Pacific Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.1.1. Key Highlights
6.1.1.1. Alkylating Agent
6.1.1.2. Plant Alkaloid
6.1.1.3. Anthracyclines
6.1.1.4. Antitumor Antibiotic
6.1.1.5. Other Drug Class
6.2. Asia Pacific Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.2.1. Key Highlights
6.2.1.1. Cervical Cancer
6.2.1.2. Uterine Cancer
6.2.1.3. Ovarian & Fallopian Tube Cancer
6.2.1.4. Vulvar Cancer
6.2.1.5. Vaginal Cancer
6.3. Asia Pacific Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.3.1. Key Highlights
6.3.1.1. Hospital Pharmacies
6.3.1.2. Retail Pharmacies
6.3.1.3. E-commerce
6.4. Asia Pacific Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.4.1. Key Highlights
6.4.1.1. Hospitals
6.4.1.2. Clinics
6.4.1.3. Specialized Cancer Treatment Centers
6.4.1.4. Other End Users
6.5. Asia Pacific Gynaecological Cancer Drugs Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1. Key Highlights
6.5.1.1. China Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.2. China Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.3. China Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.4. China Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.5. Japan Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.6. Japan Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.7. Japan Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.8. Japan Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.9. South Korea Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.10. South Korea Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.11. South Korea Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.12. South Korea Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.13. India Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.14. India Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.15. India Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.16. India Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.17. Southeast Asia Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.18. Southeast Asia Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.19. Southeast Asia Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.20. Southeast Asia Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.21. Rest of Asia Pacific Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.22. Rest of Asia Pacific Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.23. Rest of Asia Pacific Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.1.24. Rest of Asia Pacific Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
6.5.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

7.1. Latin America Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.1.1. Key Highlights
7.1.1.1. Alkylating Agent
7.1.1.2. Plant Alkaloid
7.1.1.3. Anthracyclines
7.1.1.4. Antitumor Antibiotic
7.1.1.5. Other Drug Class
7.2. Latin America Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.2.1.1. Cervical Cancer
7.2.1.2. Uterine Cancer
7.2.1.3. Ovarian & Fallopian Tube Cancer
7.2.1.4. Vulvar Cancer
7.2.1.5. Vaginal Cancer
7.3. Latin America Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.3.1. Key Highlights
7.3.1.1. Hospital Pharmacies
7.3.1.2. Retail Pharmacies
7.3.1.3. E-commerce
7.4. Latin America Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.4.1. Key Highlights
7.4.1.1. Hospitals
7.4.1.2. Clinics
7.4.1.3. Specialized Cancer Treatment Centers
7.4.1.4. Other End Users
7.5. Latin America Gynaecological Cancer Drugs Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1. Key Highlights
7.5.1.1. Brazil Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.2. Brazil Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.3. Brazil Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.4. Brazil Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.5. Mexico Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.6. Mexico Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.7. Mexico Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.8. Mexico Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.9. Argentina Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.10. Argentina Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.11. Argentina Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.12. Argentina Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.13. Rest of Latin America Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.14. Rest of Latin America Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.15. Rest of Latin America Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.1.16. Rest of Latin America Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
7.5.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, 2018 - 2031

8.1. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.1.1. Key Highlights
8.1.1.1. Alkylating Agent
8.1.1.2. Plant Alkaloid
8.1.1.3. Anthracyclines
8.1.1.4. Antitumor Antibiotic
8.1.1.5. Other Drug Class
8.2. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, by Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.2.1. Key Highlights
8.2.1.1. Cervical Cancer
8.2.1.2. Uterine Cancer
8.2.1.3. Ovarian & Fallopian Tube Cancer
8.2.1.4. Vulvar Cancer
8.2.1.5. Vaginal Cancer
8.3. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, by Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.3.1. Key Highlights
8.3.1.1. Hospital Pharmacies
8.3.1.2. Retail Pharmacies
8.3.1.3. E-commerce
8.4. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, by End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.4.1. Key Highlights
8.4.1.1. Hospitals
8.4.1.2. Clinics
8.4.1.3. Specialized Cancer Treatment Centers
8.4.1.4. Other End Users
8.5. Middle East & Africa Gynaecological Cancer Drugs Market Outlook, by Country, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1. Key Highlights
8.5.1.1. GCC Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.2. GCC Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.3. GCC Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.4. GCC Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.5. South Africa Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.6. South Africa Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.7. South Africa Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.8. South Africa Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.9. Egypt Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.10. Egypt Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.11. Egypt Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.12. Egypt Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.13. Nigeria Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.14. Nigeria Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.15. Nigeria Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.16. Nigeria Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.17. Rest of Middle East & Africa Gynaecological Cancer Drugs Market by Drug Class, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.18. Rest of Middle East & Africa Gynaecological Cancer Drugs Market Indication, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.19. Rest of Middle East & Africa Gynaecological Cancer Drugs Market Distribution Channel, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.1.20. Rest of Middle East & Africa Gynaecological Cancer Drugs Market End User, Value (US$ Mn) and Volume (Million Units), 2018 - 2031
8.5.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. Distribution Channel vs Indication Heatmap
9.2. Manufacturer vs Indication Heatmap
9.3. Company Market Share Analysis, 2022
9.4. Competitive Dashboard
9.5. Company Profiles
9.5.1. Roche Holdings AG
9.5.1.1. Company Overview
9.5.1.2. Product Portfolio
9.5.1.3. Financial Overview
9.5.1.4. Business Strategies and Development
9.5.2. AstraZeneca
9.5.2.1. Company Overview
9.5.2.2. Product Portfolio
9.5.2.3. Financial Overview
9.5.2.4. Business Strategies and Development
9.5.3. Sanofi
9.5.3.1. Company Overview
9.5.3.2. Product Portfolio
9.5.3.3. Financial Overview
9.5.3.4. Business Strategies and Development
9.5.4. Eli Lilly & Co.
9.5.4.1. Company Overview
9.5.4.2. Product Portfolio
9.5.4.3. Financial Overview
9.5.4.4. Business Strategies and Development
9.5.5. Pfizer Inc.
9.5.5.1. Company Overview
9.5.5.2. Product Portfolio
9.5.5.3. Financial Overview
9.5.5.4. Business Strategies and Development
9.5.6. Takeda Pharmaceuticals Co. Ltd.
9.5.6.1. Company Overview
9.5.6.2. Product Portfolio
9.5.6.3. Financial Overview
9.5.6.4. Business Strategies and Development
9.5.7. Bristol-Myers Squibb
9.5.7.1. Company Overview
9.5.7.2. Product Portfolio
9.5.7.3. Financial Overview
9.5.7.4. Business Strategies and Development
9.5.8. Merck & Co.
9.5.8.1. Company Overview
9.5.8.2. Product Portfolio
9.5.8.3. Financial Overview
9.5.8.4. Business Strategies and Development
9.5.9. Dr Reddy’s Laboratories
9.5.9.1. Company Overview
9.5.9.2. Product Portfolio
9.5.9.3. Financial Overview
9.5.9.4. Business Strategies and Development
9.5.10. Johnson & Johnson (Alza Corporation)
9.5.10.1. Company Overview
9.5.10.2. Product Portfolio
9.5.10.3. Financial Overview
9.5.10.4. Business Strategies and Development
9.5.11. GlaxoSmithKline (GSK)
9.5.11.1. Company Overview
9.5.11.2. Product Portfolio
9.5.11.3. Financial Overview
9.5.11.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations

Companies Mentioned

Roche Holdings AG
AstraZeneca
Sanofi
Eli Lilly & Co.
Pfizer Inc.
Takeda Pharmaceuticals CoLtd.
Bristol-Myers Squibb
Merck & Co.
Dr Reddy’s Laboratories
Johnson & Johnson (Alza Corporation)
GlaxoSmithKline (GSK)

Methodology

LOADING...

Global Gynaecological Cancer Drugs Market- Segmentation

Drug Class

End Users

Indication

Distribution Channel

Region

Table of Contents

Companies Mentioned

Methodology

Related Topics

Related Reports

Gynecology Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

Cancer Supportive Care Products Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Hyperthermia Treatment for Cancer Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Gynecological Examination Chairs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts 2019 - 2029

Oncology Biosimilars Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Drug Class, Cancer Type, and Distribution Channel